Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Elitra: Filling the antimicrobial pool

One problem in treating fungal and bacterial infections is that existing antibiotics act against a relatively limited set of targets. This limited set of products with similar mechanisms of action gives rise to rapid and extensive microbial drug resistance. Elitra Pharmaceuticals Inc. hopes to address the problem by increasing both the number of antimicrobial targets and therapeutics.

The company is developing a relational database of essential genes and

Read the full 675 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE